Make Your Voice Heard

If you have hepatitis C or are caring for someone who has hepatitis C, we would like to hear from you.

 Health Canada is currently reviewing a new drug therapy -- glecaprevir + pibrentasvir -- for hepatitis C. As part of their review, Health Canada wants to hear from liver disease patients, caregivers and health care professionals to get a sense of the personal impact of this disease, how currently available treatments are working or not working and what outcomes are most important. when considering potential new treatments. 

The Canadian Liver Foundation is preparing a submission and we invite you to be part of it by sharing your comments and personal experiences.

Please note that the CLF does not recommend any particular drug for the treatment of hepatitis C.  We believe that patients and their doctors should have access to a broad range of treatment options in order to ensure the best possible outcomes. It is up to the doctors to make individual treatment recommendations based on the needs of their patients.  Our request for input for glecaprevir + pibrentasvir is the result of a call for patient group input from Health Canada.

If you have experience with hepatitis C and would like to share your comments, please click on the link below and fill out our survey. We will compile all feedback and include it in our submission to Health Canada.

Canadian Liver Foundation survey on glecaprevir + pibrentasvir. 

The deadline for submitting your comments is 5:00pm (EDT) on Monday, June 12, 2017.

If you have any questions about the survey or the Canadian Liver Foundation's submission to Health Canada, please contact Melanie Kearns at 1-800-563-5483 or email